The Canadian shortage of the 0.3 mg format of EpiPen is due to a manufacturing disruption and is currently anticipated to be resolved by March 2, 2018.
Pfizer Canada has advised Health Canada there is currently a shortage of EpiPen auto-injectors in the 0.3 mg format. The shortage is reported to be due to a manufacturing disruption and is currently anticipated to be resolved by March 2, 2018. According to Pfizer, the shortage does not impact EpiPen Jr (0.15 mg) products, which remain available. EpiPen is used to deliver an emergency treatment of adrenaline to patients who are at risk or have a history of life-threatening allergic reactions (anaphylaxis). There are currently no alternative auto-injectors available on the market in Canada. EpiPen auto-injectors expire on the last day of the month as indicated on the product packaging. However, in this shortage situation, if an individual is experiencing an anaphylactic reaction, Health Canada advises Canadians to use the expired product and immediately contact 911. - Health Canada Release